An EAP Treatment Protocol of Zipalertinib

Summary

"Only licensed physicians may submit an email inquiry/question about Taiho's Zipalertinib Expanded Access Program via email ([email protected]). If you are a patient or caregiver, do not email Parexel or Taiho. Please talk to your physician. Do not share any patient Personally Identifiable Information with Parexel." The objective of the study is to provide access to zipalertinib to patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations whose disease has progressed on or after platinum-based chemotherapy with or without amivantamab.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications